BG
Bellevue Group Portfolio holdings
AUM
$4.54B
This Quarter Return
+46.01%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$7.07B
AUM Growth
+$7.07B
(+37%)
Cap. Flow
+$60.6M
Cap. Flow
% of AUM
0.86%
Top 10 Holdings %
Top 10 Hldgs %
40.22%
Holding
231
New
17
Increased
84
Reduced
52
Closed
23
Top Buys
| 1 |
Edwards Lifesciences
EW
|
$38.5M |
| 2 |
Generation Bio
GBIO
|
$30.2M |
| 3 |
Stryker
SYK
|
$27.2M |
| 4 |
Insulet
PODD
|
$25.1M |
| 5 |
Bristol-Myers Squibb
BMY
|
$23.9M |
Top Sells
| 1 |
Vertex Pharmaceuticals
VRTX
|
$84.3M |
| 2 |
Moderna
MRNA
|
$38.9M |
| 3 |
Illumina
ILMN
|
$38.1M |
| 4 |
Intuitive Surgical
ISRG
|
$36.5M |
| 5 |
MacroGenics
MGNX
|
$31.2M |
Sector Composition
| 1 | Healthcare | 96.05% |
| 2 | Industrials | 0.58% |
| 3 | Technology | 0.42% |
| 4 | Communication Services | 0.29% |
| 5 | Financials | 0.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
126
AbbVie
ABBV
$372B
| $3.63M | 0.05% |
37,000
+11,600
| +46% | +$1.14M |
|
127
BioNTech
BNTX
$24B
| $3.34M | 0.05% |
+50,000
| New | +$3.34M |
|
128
Sarepta Therapeutics
SRPT
$1.78B
| $3.26M | 0.05% |
20,300
+300
| +2% | +$48.1K |
|
129
Sanofi
SNY
$121B
| $2.91M | 0.04% |
+57,000
| New | +$2.91M |
|
130
PTC Therapeutics
PTCT
$3.92B
| $2.88M | 0.04% |
56,800
-8,400
| -13% | -$426K |
|
|
BMY.RT
131
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
| $2.86M | 0.04% |
800,000
-16,600
| -2% | -$59.4K |
|
|
MNTA
132
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $2.48M | 0.04% |
74,400
+7,000
| +10% | +$233K |
|
133
Acadia Pharmaceuticals
ACAD
$4.38B
| $2.18M | 0.03% |
44,900
+2,900
| +7% | +$141K |
|
|
MRTX
134
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $2.03M | 0.03% |
17,800
+1,900
| +12% | +$217K |
|
135
Ascendis Pharma
ASND
$11.8B
| $1.97M | 0.03% |
13,300
+1,400
| +12% | +$207K |
|
136
Dr. Reddy's Laboratories
RDY
$11.8B
| $1.96M | 0.03% |
+37,000
| New | +$1.96M |
|
137
Ultragenyx Pharmaceutical
RARE
$2.89B
| $1.88M | 0.03% |
24,000
+2,500
| +12% | +$196K |
|
138
Vir Biotechnology
VIR
$686M
| $1.74M | 0.02% |
+42,500
| New | +$1.74M |
|
139
uniQure
QURE
$896M
| $1.56M | 0.02% |
34,500
+3,000
| +10% | +$135K |
|
140
Regenxbio
RGNX
$451M
| $1.51M | 0.02% |
41,000
+4,100
| +11% | +$151K |
|
|
CLLS
141
Cellectis
CLLS
$258M
| $1.49M | 0.02% |
83,500
+8,200
| +11% | +$146K |
|
|
BNR
142
Burning Rock Biotech
BNR
$93.6M
| $1.22M | 0.02% |
+45,000
| New | +$1.22M |
|
|
GTH
143
DELISTED
Genetron Holdings Limited ADS
GTH
| $1.21M | 0.02% |
+100,000
| New | +$1.21M |
|
|
YI
144
111 Inc
YI
$55.7M
| $1.08M | 0.02% |
170,525
+55,096
| +48% | +$350K |
|
|
NARI
145
DELISTED
Inari Medical, Inc. Common Stock
NARI
| $727K | 0.01% |
+15,000
| New | +$727K |
|
146
Electronic Arts
EA
$43B
| $617K | 0.01% |
4,670
-130
| -3% | -$17.2K |
|
147
Pool Corp
POOL
$11.6B
| $598K | 0.01% |
2,200
| – | – |
|
148
McKesson
MCK
$85.4B
| $597K | 0.01% |
3,892
| – | – |
|
149
Match Group
MTCH
$8.98B
| $567K | 0.01% |
5,300
| – | – |
|
150
Mettler-Toledo International
MTD
$26.8B
| $564K | 0.01% |
700
| – | – |
|